Lorbriqua 25mg Tablet 15's

About

Lorbriqua 25mg Tablet is a potent, orally available tyrosine kinase inhibitor (TKI) specifically designed to target anaplastic lymphoma kinase (ALK) and ROS1 fusions, which are well-established oncogenic drivers in certain types of non-small cell lung cancer (NSCLC). By selectively inhibiting these aberrant kinases, Lorbriqua disrupts downstream signaling pathways essential for cancer cell proliferation, survival, and metastasis. This targeted mechanism allows for effective disease control in patients whose tumors harbor these specific genetic alterations, particularly in cases of acquired resistance to earlier generation ALK inhibitors. Furthermore, Lorbriqua demonstrates significant intracranial activity, making it a crucial therapeutic option for patients with central nervous system metastases, a common challenge in advanced NSCLC.

Uses

• Treatment of ALK-positive metastatic non-small cell lung cancer.
• Management of ROS1-positive metastatic non-small cell lung cancer.
• Therapy for patients who have progressed on prior ALK inhibitors.
• Effective against brain metastases in ALK-positive NSCLC.

Directions For Use

Take Lorbriqua 25mg Tablet orally once daily, with or without food, as directed by your oncologist. Swallow the tablet whole; do not crush or chew.

Benefits

• Highly effective against ALK and ROS1 positive NSCLC.
• Demonstrates efficacy in patients resistant to other TKIs.
• Penetrates the blood-brain barrier, treating brain metastases.
• Offers a targeted approach with improved response rates.
• Provides a significant survival benefit in eligible patients.
• Improves quality of life by controlling disease progression.

Side Effects

• Peripheral edema
• Hypercholesterolemia
• Hypertriglyceridemia
• Cognitive effects (e.g., memory impairment)
• Mood changes
• Fatigue
• Myalgia
• Diarrhea
• Nausea
• Elevated liver enzymes
• Hypertension
• Visual disturbances

Safety Measures

• Alcohol - Avoid excessive alcohol consumption, as it may contribute to liver enzyme elevations or exacerbate gastrointestinal side effects.
• Pregnancy - Lorbriqua is embryofetal toxic. Women of reproductive potential must use effective contraception during treatment and for at least 6 months after the last dose.
• Breastfeeding - Breastfeeding is not recommended during treatment with Lorbriqua and for 7 days after the last dose, due to potential serious adverse reactions in the infant.
• Liver - Monitor liver function tests regularly. Dose adjustments may be necessary in patients with moderate to severe hepatic impairment.
• Kidney - No dose adjustment is typically required for mild to moderate renal impairment. Use with caution in severe renal impairment.
• Lung - Monitor for new or worsening respiratory symptoms, as interstitial lung disease/pneumonitis can occur. Discontinue if confirmed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.